Otigo® (phenazone/lidocaine hydrochloride) 40 mg/10 mg/g ear drops, solution
Information intended for UK healthcare professionals only. This formulary decision guide was developed from content provided by LogixX Pharma Limited in a format developed by Guidelines in Practice. Renascience Pharma Limited carried out full medical approval to ensure compliance with regulations.
View Otigo® (phenazone/lidocaine hydrochloride) prescribing information and adverse event reporting information here
OTI-UK-028-SP
Date of preparation: June 2022
Sixmo®▼ (buprenorphine) 74.2 mg implant
Information intended for UK healthcare professionals only. This formulary decision guide was developed from content provided by Accord Healthcare Limited in a format developed by Guidelines in Practice.
View prescribing information and adverse event reporting information.
UK-03417
Date of preparation: October 2021
Ipinnia® XL (ropinirole hydrochloride) prolonged-release tablets
This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-IPN-13 Date of preparation: September 2021
Xaggitin XL (methylphenidate hydrochloride) prolonged-release tablets
This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-XAG-20 Date of preparation: July 2021